Hui Xie, Sheng-Tao Tian, Zhao Yang, Hua-Ming Wang,
Department of Interventional Therapy, 302 Hospital of People’s Liberation Army, Beijing 100039, China

Yao-Qin Xue, Zhi Guo,
Department of Interventional Therapy,
Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin, Tianjin’s Clinical Research Center for Cancer, Tianjin 300070, China

Yao-Qin Xue,
Department of Interventional Therapy, Shanxi Province Cancer Hospital, Shanxi Medical University, Taiyuan 030000, Shanxi Province, China

Peng Liu, Peng-Jun Zhang,
Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Interventional Therapy Department, Peking University Cancer Hospital and Institute, Beijing 100142, China

Author contributions: Xie H, Yao Q, Liu P, Guo Z and Wang HM designed the study; Xie H, Yao Q and Liu P performed the research; Xie H, Zhang P, Tian ST and Zhao Y analyzed the data; Xie H, Yao Q and Liu P wrote the paper; Guo Z and Wang HM revised the manuscript for final submission; Xie H, Yao Q and Liu P contributed equally to this study; Guo Z and Wang HM are the co-corresponding authors.

Supported by National Key R&D Program of China, No. 2016YFC0106604, and National Natural Science Foundation of China, No. 81471761 and No. 81501568.

Institutional review board statement: The study was reviewed and approved by the 302 Hospital of People’s Liberation Army Institutional Review Board.

Informed consent statement: All study participants or their legal guardian provided written informed consent prior to study enrollment.

Conflict-of-interest statement: We declare that we have no financial or personal relationships with other individuals or organizations that can inappropriately influence our work and that there is no professional or other personal interest of any nature in any product, service and/or company that could be construed as influencing the position presented in or the review of the manuscript.

Data sharing statement: The study participants provided informed consent for data sharing. No additional data are available.

Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

Manuscript source: Unsolicited manuscript

Correspondence to: Hua-Ming Wang, BCPS, MD, Chief Doctor, Professor, Department of Interventional Therapy, 302 Hospital of People’s Liberation Army, 100 Middle West 4th Ring Road, Fengtai District, Beijing 100039, China. hmwang302@126.com
Telephone: +86-10-66933263
Fax: +86-10-66933263

Received: August 9, 2017
Peer-review started: August 9, 2017
First decision: August 29, 2017
Revised: October 16, 2017
Accepted: November 21, 2017
Article in press: November 21, 2017
Published online: January 21, 2018

Abstract

AIM
In our previous study, we have built a nine-gene (GPC3, HGF, ANXA1, FOS, SPAG9, HSPA1B, CXCR4, PFN1, and CALR) expression detection system based on the GeXP system. Based on peripheral blood and GeXP, we
aimed to analyze the results of genes expression by different multi-parameter analysis methods and build a diagnostic model to classify hepatocellular carcinoma (HCC) patients and healthy people.

METHODS
Logistic regression analysis, discriminant analysis, classification tree analysis, and artificial neural network were used for the multi-parameter gene expression analysis method. One hundred and three patients with early HCC and 54 age-matched healthy normal controls were used to build a diagnostic model. Fifty-two patients with early HCC and 34 healthy people were used for validation. The area under the curve, sensitivity, and specificity were used as diagnostic indicators.

RESULTS
Artificial neural network of the total nine genes had the best diagnostic value, and the AUC, sensitivity, and specificity were 0.943, 98%, and 85%, respectively. At last, 52 HCC patients and 34 healthy normal controls were used for validation. The sensitivity and specificity were 96% and 86%, respectively.

CONCLUSION
Multi-parameter analysis methods may increase the diagnostic value compared to single factor analysis and they may be a trend of the clinical diagnosis in the future.

Key words: Hepatocellular carcinoma; Peripheral blood; Early detection; Multi-parameter; Diagnostic value

© The Author(s) 2018. Published by Baishideng Publishing Group Inc. All rights reserved.

Core tip: We aimed to analyze the results of expression of nine genes, which we identified previously, by different multi-parameter analysis methods and build a diagnostic model to classify hepatocellular carcinoma patients and healthy people. Logistic regression analysis, discriminant analysis, classification tree analysis, and artificial neural network were used for the multi-parameter gene expression analysis.

Xie H, Xue YQ, Liu P, Zhang PJ, Tian ST, Yang Z, Guo Z, Wang HM. Multi-parameter gene expression profiling of peripheral blood for early detection of hepatocellular carcinoma. World J Gastroenterol 2018; 24(3): 371-378 Available from: URL: http://www.wjgnet.com/1007-9327/full/v24/i3/371.htm DOI: http://dx.doi.org/10.3748/wjg.v24.i3.371

INTRODUCTION
Hepatocellular carcinoma (HCC) is one of the most common cancers in the world[1]. Chronic infection with hepatitis B or C virus, dietary aflatoxin B1 intake, and alcohol abuse clearly show a significant correlation with the incidence of HCC. In China, more than 90% of HCC patients are reported to experience chronic HBV infection[2]. Currently, HCC is often diagnosed at an advanced stage and has a poor prognosis. Clinical practice has demonstrated that early diagnosis of HCC can significantly increase the survival time. Many biomarkers have been proposed, and some are currently used in clinical diagnosis[3,4]; however, even alpha-fetoprotein, the most widely used biomarker for HCC diagnosis, has a poor diagnostic value[5]. Although pathology is used as a gold standard for diagnosis of HCC, it is invasive, and tissue samples are not easily obtained. Therefore, a non-invasive, accurate, and fast method for early detection of HCC is urgently needed.

Peripheral blood samples, which are easily and repeatedly obtained in the clinical setting, have been demonstrated to be valuable for disease prediction and classification, drug response evaluation, and toxicity classification[6-8]. These features make peripheral blood samples attractive to aid in the early detection of HCC[9]. As we know, HCC is a complex multi-gene and multi-fatorial disease, and a single biomarker is not adequate to reflect the HCC status. A panel of biomarkers is a promising method for early detection of HCC, and some panels have been used for cancer prediction[10,11]. A single gene analysis method is not sufficient when gene expression is used for diagnosis. Multi-parameter analysis methods, such as logistic regression analysis (LRA), discriminant analysis (DA), classification tree analysis (CTA), and artificial neural network (ANN), which can analyze multiple factors, have been shown to increase the diagnostic sensitivity and specificity and may be promising analysis methods for multi-parameter analysis[12-14].

In our previous study, we used Affymetrix to screen differential gene expression and built a 9-gene (GPC3, HGF, ANXA1, FOS, SPAG9, HSPA1B, CXCR4, PFN1, and CALR) expression detection system based on the GenomeLab GeXP Genetic Analysis system[15], known as GeXP, which can detect up to 35 genes in one reaction[16]. Based on peripheral blood and GeXP, we compared multi-parameter gene expression using various multi-parameter analysis methods and built a diagnostic model to classify early-stage HCC patients and healthy people.

MATERIALS AND METHODS
Patients and blood collection
The study was reviewed and approved by the 302 Hospital of People’s Liberation Army Institutional Review Board. After obtaining patient consent, blood samples from 103 early-stage HCC patients with chronic HBV infection were collected at our hospital. Fifty-four age-matched healthy normal control samples were collected from the people who underwent a health examination. Both samples were used to build the diagnostic
model. Fifty-two early-stage HCC patients and 34 healthy people were used for validation. The disease status of early-stage HCC patients was confirmed by histopathological analysis, and tumors were staged according to the Barcelona Clinic Liver Cancer (BCLC) staging classification as either T1 (single lesion < 2 cm in diameter) or T2 (single lesion between 2 and 5 cm in diameter or < 3 lesions, each of which was < 3 cm in diameter)\(^{[17]}\). In addition, peripheral blood from HCC patients was collected before any therapy. The clinical characteristics of all the samples used for this study are shown in Table 1.

Peripheral blood (2.5 mL) was collected and added into the PAXGene blood RNA tubes (Qiagen, Valencia, CA, United States). After inverting, the tubes were stored at -80 °C until total RNA extraction.

**RNA isolation and GeXP gene expression detection**

Total RNA was isolated using the PAXGene Blood RNA Kit (Qiagen, Valencia, CA, United States) according to the manufacturer's instructions. The quality and quantity of RNA were measured by agarose gel electrophoresis and DU 800 spectrophotometry (Beckman Coulter, Fullerton, CA, United States), respectively. The primers for the nine genes were shown in our previous study. Reverse and forward primers were diluted 1:200 and 1:500 in nuclease-free water to a final concentration of 500 nmol/L and 200 nmol/L, respectively. Total RNA (50 ng) was used for reverse transcription (RT) with chimeric reverse primers in a single reaction. The concentrations of the primers were diluted at a ratio of 1:8. The RT reactions were performed using the following parameters: 48 °C for 1 min, 42 °C for 60 min, 95 °C for 5 min, and then held at 4 °C.

Polymerase chain reaction (PCR) reaction (10 μL) was performed in the 96-well PCR Detection Plate using the following parameters: 95 °C for 10 min, followed by 35 cycles of 94 °C for 30 s, 55 °C for 30 s, and 68 °C for 1 minute. The PCR products were diluted using nuclease-free water and added to the detection plate, which contained sample loading solution and DNA Size Standard 400. The GeXP system was used to match each gene fragment size and to measure the fluorescent dye signal strength in arbitrary units, and then the dataset was normalized to the housekeeping gene B2M. Finally, the dataset was log transformed.

**Multi-parameter gene expression analysis**

LRA\(^{[18,19]}\), DA\(^{[20,21]}\), CTA\(^{[22,23]}\), and ANN analysis\(^{[24,25]}\) were used as the multi-parameter gene expression analysis methods. In LRA, the "Forward: Conditional" method was used to select variables. The stepwise probability was "Entry 0.05" and "Removal 0.10", the "Probabilities" was saved, and then "CI for exp (B) 95%" was shown. The "Probabilities" of the HCC group were used for receiver operating characteristic (ROC) analysis, and the cutoff value was based on the Youden Index. In DA, "Use stepwise method" was used to select variables. The stepwise criterion was the "F value". The "Entry" was 3.84, and the "Removal" was 2.71. The "Probabilities of group membership" was saved as a new variable, "Dis_n," which represented the probability of HCC, and then the "Probabilities of group membership" was used for ROC analysis. In the CTA, "Exhaustive CHAID" was used as a growth method, and 20% of the samples were selected as the validation samples. The "Predicted value" was saved as a new variable for the ROC analysis. In the ANN analysis, the ROC curve was saved, and 80% of the samples were used as the training group and 20% as the test group. After comparison, the best diagnostic model was chosen, and 52 HCC samples and 34 healthy normal controls were used to validate the model. The ROC curve, area under the curve (AUC), sensitivity, and specificity were used as diagnostic indicators.

**RESULTS**

**Genes used for diagnostic evaluation**

A total of nine genes (GPC3, HGF, ANXA1, FOS, SPAG9, HSPA1B, CXCR4, PFN1, and CALR) were used for HCC detection. We used the ROC curve of the

---

**Table 1  Characteristics of early-stage hepatocellular carcinoma and healthy control samples**

| Variable                                | HCC (Number of Patients) | Control (Number of Patients) | HCC (Model validation) | Control (Model validation) |
|------------------------------------------|--------------------------|------------------------------|------------------------|----------------------------|
| Number of patients                       | 103                      | 54                           | 52                     | 34                         |
| Male                                     | 54                       | 29                           | 29                     | 19                         |
| Female                                   | 49                       | 25                           | 23                     | 15                         |
| Age (mean ± SD)                          | 54 ± 12                  | 49 ± 11                      | 51 ± 14                | 52 ± 9                     |
| Tumor size (> 3 cm)                      | 29                       | 0                            | 13                     | 0                          |
| Tumor size (< 3 cm)                      | 74                       | 0                            | 39                     | 0                          |
| Number of nodules (Unilocular)           | 36                       | 0                            | 21                     | 0                          |
| Number of nodules (Multilocular)         | 67                       | 0                            | 31                     | 0                          |
| Cirrhosis                                | 89                       | 0                            | 36                     | 0                          |
| BCLC stage (T1)                          | 27                       | 0                            | 19                     | 0                          |
| BCLC stage (T2)                          | 76                       | 0                            | 32                     | 0                          |

HCC: Hepatocellular carcinoma.
nine genes to evaluate the diagnostic value and then analyzed the $P$-value and 95% confidence interval (CI). The diagnostic value of the AUC, the $P$-value, 95% confidence interval, cutoff value, sensitivity, and specificity are shown in Table 2. The ROC curves from four genes ($HGF$, $ANXA1$, $SPAG9$, and $PFN1$) showed $P$-values less than 0.05. According to the $P$-values, four genes ($HGF$, $ANXA1$, $SPAG9$, and $PFN1$) were chosen to have diagnostic value. In the multi-parameter analysis, both the 9-gene and the 4-gene sets were used.

**Multi-parameter LRA**

In the LRA for HCC detection, we compared the diagnostic value of the full 9-gene set ($GPC3$, $HGF$, $ANXA1$, $FOS$, $SPAG9$, $HSPA1B$, $CXCR4$, $PFN1$, and $CALR$) and the 4-gene set ($HGF$, $ANXA1$, $SPAG9$, and $PFN1$). From the full 9-gene set, five genes were selected using a "Forward: Conditional" method. The diagnostic formula was as follows:

$$Y = -4.089 + 21.269 \times X_{ANXA1} - 5.339 \times X_{FOS} + 32.543 \times X_{SPAG9} - 2.743 \times X_{CXCR4} + 9.524 \times X_{PFN1} \quad (Y = \text{logit } P)$$

In the 4-gene set, three genes were selected, and the diagnostic formula was as follows:

$$Y = -4.826 + 13.172 \times X_{ANXA1} + 15.353 \times X_{SPAG9} + 8.755 \times X_{PFN1} \quad (Y = \text{logit } P)$$

Then, the probability was used for evaluating the diagnostic value. The ROC curves are shown in Figure 1. The AUC of the five selected genes was 0.933, and that of the three selected genes was 0.878. This indicated that the five selected genes had better diagnostic value, and when the cutoff of logit $P$ was 0.548, the sensitivity and specificity were 94% and 80%, respectively. According to the diagnostic formula, we can know the risk of the detected sample. In addition, the odds ratio (OR) of the five selected genes was also analyzed and is shown in Table 3. An OR greater than 1 indicates that the factor is a risk factor for the disease, and an OR less than 1 means it is a protective factor. Thus, the $ANXA1$, $SPAG9$, and $PFN1$ genes were risk factors. When their gene expression is higher, it may decrease the incidence of HCC. The $FOS$ and $CXCR4$ genes were found to be protective factors. When their gene expression is higher, it may decrease the incidence of HCC.

**Multi-parameter DA**

In the DA, the full 9-gene set was analyzed by Bayes DA. Six genes were selected by "Use stepwise method". The following formulas were used separately:

$$Y_1 = -7.306 + 8.078 \times X_{GPC3} + 20.770 \times X_{ANXA1} - 3.414 \times X_{FOS} + 12.652 \times X_{SPAG9} + 1.842 \times X_{CXCR4} + 18.248 \times X_{PFN1}$$

$$Y_2 = -5.612 + 15.760 \times X_{GPC3} + 4.432 \times X_{ANXA1} + 1.585 \times X_{FOS} - 10.298 \times X_{SPAG9} + 4.320 \times X_{CXCR4} + 12.370 \times X_{PFN1}$$

In the 4-gene set, three genes entered the diagnostic formulas. The formulas were as follows:

$$Y_1 = -6.665 + 21.814 \times X_{ANXA1} + 18.524 \times X_{SPAG9} + 16.663 \times X_{PFN1}$$

$$Y_2 = -2.806 + 13.784 \times X_{ANXA1} + 8.081 \times X_{SPAG9} + 10.393 \times X_{PFN1}$$

The probability of the healthy normal group and the HCC group analyzed by the three selected genes was saved as a new variable named Dis 1. The probability of the six selected genes was saved as Dis 2. The new variables Dis 1 and Dis 2 were used for the ROC analysis, as shown in Figure 2. The AUC of Dis 1 was 0.877 and of Dis 2 was 0.926. This result meant that the six selected genes had better diagnostic value for HCC, and when the cutoff of $Y$ was 0.628, the sensitivity and specificity were 82% and 89%, respectively.

**Multi-parameter CTA**

We compared the diagnostic value of the full 9-gene set and the 4-gene set by CTA; however, only $ANXA1$ entered the classification tree. The classification tree of the full 9-gene set was the same as the 4-gene set, as shown in Figure 3. When the cutoff was 0.629, the sensitivity and specificity were 78% and 60%, respectively. The total accuracy was only 66.20%.

**Multi-parameter ANN analysis**

The full 9-gene set and the 4-gene set were then analyzed by the ANN method; their network had one hidden layer which contained five units. In the training...
In the total nine genes, five (ANXA1, FOS, SPAG9, CXCR4, and PFN1) entered the formula. In the four genes, three (ANXA1, SPAG9, and PFN1) entered the formula. The probability was used for ROC analysis. The AUC of the five selected genes was 0.933 and that of the three selected genes was 0.878, indicating that the five selected genes had better diagnostic value, and the sensitivity and specificity were 94% and 80%, respectively.

Comparison of multiple multi-parameter analysis methods and validation
Multiple multi-parameter analysis methods were used to build models, and the AUC was used to evaluate the diagnostic value. When a single gene was used, the AUC of SPAG9 was greater than those of the other genes. The AUCs of LRA, DA, and ANN were greater than that of SPAG9, and the AUC of CTA was less than that of SPAG9. Among the methods, the ANN of the full 9-gene set had the best diagnostic value; the AUC was less than that of the full 9-gene set. The AUC of the full 9-gene set was 0.943, greater than that of the 4-gene set, which was 0.877.

DISCUSSION
Clinical peripheral blood samples can be obtained easily and in a minimally invasive way. Studies have shown that mRNA in peripheral blood has the potential to be used for the early detection of cancers. There are many mRNA detection methods; however, the most commonly used method, real-time PCR, is limited by variations in amplification efficiency across multiple genes. This demonstrated that genes with more significant differences between groups, and even if they had poor diagnostic value, also entered the formula. This demonstrated that the genes showed significant differences between groups, and even if they had AUC values of less than 0.5, they may contribute to the logistic analysis. In the 4-gene set, three genes (ANXA1, SPAG9, and PFN1) entered the formula; however, FOS and CXCR4, which had poor diagnostic value, also entered the formula. This demonstrated that genes showed significant differences between groups, and even if they had AUC values of less than 0.5, they may contribute to the logistic analysis. In the 4-gene set, three genes (ANXA1, SPAG9, and PFN1) entered the formula; however, FOS and CXCR4, which had poor diagnostic value, also entered the formula. This demonstrated that genes with more significant differences may result in better diagnostic values.
The logistic had a formula which can get a continuous value: logit (P). With a gene expression panel, we can predict the P-value to differentiate healthy people and HCC patients, which may provide a clinical indication for both physicians and patients.

After OR analysis, the ANXA1, SPAG9, and PFN1 genes were detected as risk factors. The FOS and CXCR4 genes were protective factors. Annexin1 (ANXA1) is a member of the annexin family of phospholipid-binding and calcium-binding proteins with a well-demonstrated role in early delayed inhibitory feedback of glucocorticoids in the hypothalamus and pituitary gland[28]. Studies have demonstrated that ANXA1 is involved in tumorigenesis and can increase the incidence of HCC[29]. SPAG9 (sperm associated antigen 9) is a gene encoding c-Jun-amino-terminal kinase-interacting protein 4. This enzyme is a scaffolding protein that connects the mitogen-activated protein kinases to related transcription factor targets for the activation of JNK signaling pathways[30]. SPAG9 was also demonstrated to be a biomarker for breast cancer and cervical carcinoma[31,32]. Profilin-1 (PFN1) has been regarded as a tumor-suppressor molecule for breast cancer, and it can enhance ADP-to-ATP exchange on G-actin. In addition, it can also act as a shuttle to deliver ATP-bound G-actin to facilitate actin polymerization[33]. Studies have demonstrated that PFN1 is overexpressed in cancer cells by up-regulating PTEN and down-regulating AKT, and it is also an inhibitor of mammary carcinoma aggressiveness[34]. If PFN1 is silenced, it can inhibit endothelial cell proliferation, migration, and morphogenesis[35]. All three genes may contribute to the development of HCC.

In the DA, the AUC was similar to the logistic analysis. This demonstrated that it may be a valuable analysis method; however, because it had strict demand on the data distribution, its application was greatly limited. In our study, although we got the discriminant formula, it may have high bias because the dataset was not normally distributed. In the CTA, only one gene had diagnostic value. This finding demonstrated that they were not suitable for our study. ANN analysis has been demonstrated to provide better diagnostic value in disease prediction and cancer early detection. In our study, ANN had the best diagnostic value compared to the other analysis methods, and the predicted probabilities of the groups were also shown. In addition, in the training group for the full 9-gene set, the percent incorrect prediction was 12.3%, and for the testing group, it was 9.1%. All of these demonstrate that the ANN model we built was successful.

In our previous study, we screened the mRNA in peripheral blood samples by Affymetrix GeneChip analysis, and nine genes (GPC3, HGF, ANXA1, FOS, SPAG9, HSPA1B, CXCR4, PFN1, and CALR) were used for differentiating the healthy normal control and HCC groups. We have now built an ANN detection system. The sensitivity and specificity were 96% and 86%, respectively, which were greater than those of single-gene analysis.

**ARTICLE HIGHLIGHTS**

**Research background**
We have built a 9-gene (GPC3, HGF, ANXA1, FOS, SPAG9, HSPA1B, CXCR4, PFN1 and CALR) expression detection system based on the GeXP system in our previous study. We aimed to analyze the results of gene expression by different multi-parameter analysis methods and build a diagnostic model to classify hepatocellular carcinoma (HCC) patients and healthy people.

**Research motivation**
Although pathology is used as a golden standard for diagnosis of HCC, it is invasive and tissue sample is not easily obtained. Therefore, a non-invasive, accurate, and fast method for early detection of HCC is pressing.

**Research objectives**
A non-invasive, accurate, and fast method for early detection of HCC may be provided by our research based on the mRNA in peripheral blood.

**Research methods**
We have successfully built an artificial neural network detection system combining detection system and bioinformatics together for differentiating the healthy normal group and HCC group. The sensitivity and specificity were separately 96% and 86%, respectively, which were greater than those of single-
gene analysis.

**Research results**
Artificial neural network of the total nine genes had the best diagnostic value, and the AUC, sensitivity, and specificity were 0.943, 98%, and 85%, respectively. At last, 52 HCC patients and 34 healthy normal controls were used for validation. The sensitivity and specificity were 98% and 98%, respectively.

**Research conclusions**
Based on the mRNA in peripheral blood, a multi-parameter analysis method was used to analyze multiple genes, which may increase the diagnostic value compared to the single factor analysis for the early detection of HCC, and it may be a trend of the clinical diagnosis in the future. It may provide a non-invasive, accurate, and fast method for early detection of HCC.

**Research perspectives**
The GeXP system uses a universal priming strategy to decrease the variations in amplification efficiency across multiple genes, and it is an ideal multiple-gene biomarker discovery platform. The use of discrete characters in discriminant analysis for diagnosis of hepatocellular carcinoma and cholangiocarcinoma: clinical and prognostic implications. Oncotarget 2017; 8: 14192-14220 [PMID: 28077782 DOI: 10.18632/oncotarget.13297]

**REFERENCES**

1. Parkin DM, Bray FI, Devesa SS. Cancer burden in the year 2000. *Eur J Cancer* 2001; 37 Suppl 8: 54-566 [PMID: 11602373]
2. Gao JD, Shao YF, Xu Y, Ming LH, Wu ZY, Liu GT, Wang XH, Gao WH, Sun YT, Feng XL, Liang LM, Zhang YH, Sun ZT. Tight association of hepatocellular carcinoma with HBV infection in North China. *Hepatobiliary Pancreat Dis Int* 2005; 4: 46-49 [PMID: 15730918]
3. Berretta M, Cavaliere C, Alessandrini L, Stanzione B, Facchini G, Balestrieri L, Perin T, Canzonieri V. Serum and tissue markers in hepatocellular carcinoma and cholangiocarcinoma: clinical and prognostic implications. *Oncotarget* 2017; 8: 14192-14220 [PMID: 28077782 DOI: 10.18632/oncotarget.13297]
4. Xu J, Li J, Zheng TH, Bai L, Liu ZJ. MicroRNAs in the Occurrence and Development of Primary Hepatocellular Carcinoma. *Adv Clin Exp Med* 2016; 25: 971-975 [PMID: 28028963 DOI: 10.17219/acem/36460]
5. El-Serag HB, Marrero JA, Rudolph L, Reddy KR. Diagnosis and treatment of hepatocellular carcinoma. *Gastroenterology* 2008; 134: 1752-1763 [PMID: 18471552 DOI: 10.1053/j.gastro.2008.02.090]
6. Wang Y, Barbacioru CC, Shiffman D, Balaubramanian S, Iakoubova O, Tenuilli M, Albornoz G, Blake J, Mehmert MN, Nkadomo D, Pouler K, Chan F, Samaha RR, Eleftheriades JA. Gene expression signature in peripheral blood detects thoracic aortic aneurysm. *PLoS One* 2007; 2: e1050 [PMID: 17940614 DOI: 10.1371/journal.pone.0001050]
7. Kuzman MR, Medved V, Terzi J, Kraic D. Genome-wide analysis of peripheral blood identifies candidate biomarkers for schizophrenia. *J Psychiatr Res* 2009; 43: 1073-1077 [PMID: 19358997 DOI: 10.1016/j.jpsychires.2009.03.005]
8. Alouso V, Neves AF, Marangoni K, Faria PC, Freschi AP, Capanelli AC, Meola J, Goulart LR. Gene expression profile in the peripheral blood of patients with prostate cancer and benign prostate hyperplasia. *Cancer Detect Prev* 2009; 32: 336-337 [PMID: 19026495 DOI: 10.1016/j.cdpro.2008.10.001]
9. Yin CQ, Yuan CH, Qu Z, Guan Q, Chen H, Wang FB. Liquid Biopsy of Hepatocellular Carcinoma: Circulating Tumor-Derived Biomarkers. *Dis Markers* 2016; 2016: 1427849 [PMID: 27403030 DOI: 10.1155/2016/1427849]
10. Paczinsky S, Krijanovski OL, Braun TM, Choi SW, Clouthier SG, Kucik R, Misek DE, Cooke KR, Kirke CL, Weyand A, Bickley D, Jones D, Whitfield J, Reddy P, Levine JE, Hanash SM, Ferrara JL. A biomarker panel for acute graft-versus-host disease. *Blood* 2009; 113: 273-278 [PMID: 18832652 DOI: 10.1182/blood-2008-07-167098]
11. Aaron J, Lindahl T, Dumeaux V, Saebo S, Tobin D, Hagen N, Skaane P, Lönneborg A, Sharma P, Barrestrade-Dale AL. Gene expression profiling of peripheral blood cells for early detection of breast cancer. *Brast Cancer Res* 2010; 12: R7 [PMID: 20078854 DOI: 10.1186/bcr2472]
12. Han M, Liew CT, Zhang HW, Chao S, Zheng R, Yip KT, Song ZY, Li HM, Geng XP, Zhu LX, Lin JJ, Marshall KW, Liew CC. Novel blood-based, five-gene biomarker set for the detection of colorectal cancer. *Clin Cancer Res* 2008; 14: 455-460 [PMID: 18203981]
13. Liew CC, Ma J, Tang HC, Zheng R, Dempsey AA. The peripheral blood transcriptome dynamically reflects system wide biology: a potential diagnostic tool. *J Lab Clin Med* 2006; 147: 126-132 [PMID: 16503242 DOI: 10.1016/j.lab.2005.10.005]
14. Osman I, Bajorin DF, Sun TT, Zhong H, Douglas D, Scagertood J, Zheng R, Han M, Marshall KW, Liew CC. Novel blood biomarkers of human urinary bladder cancer. *Clin Cancer Res* 2006; 12: 3374-3380 [PMID: 16740760 DOI: 10.1158/1078-0432.CCR-05-2081]
15. Zhang PJ, Run WW, P L, Wang CB, Deng XW, Wang BB, Chen BB, J J, Liu HY, Dong ZN, Zhang XJ, Tian YP. Peripheral blood mRNA expression patterns to differentiate hepatocellular carcinoma from other hepatic diseases. *Front Biosci* (Elite Ed) 2012; 4: 620-630 [PMID: 22201899 DOI: 10.2741/e404]
16. Rai AJ, Kamath RM, Gerald W, Fleisher M. Analytical validation of the GeXP analyzer and design of a workflow for early detection of cancer: biomarker discovery using multiplexed gene-expression profiling. *Anal Bioanal Chem* 2009; 393: 1505-1511 [PMID: 18958454 DOI: 10.1007/s00216-009-0243-7]
17. Llovet JM, Fuster J, Bruix J. Barcelona-Clinic Liver Cancer Group. The Barcelona approach: diagnosis, staging, and treatment of hepatocellular carcinoma. *Liver Transpl* 2004; 10: S115-S120 [PMID: 14762851 DOI: 10.1002/lt.20034]
18. Zhou X, Liu KY, Wong ST. Cancer classification and prediction using logistic regression with Bayesian gene selection. *J Biomed Inform* 2004; 37: 249-259 [PMID: 15465478 DOI: 10.1016/j.jbi.2004.07.009]
19. Elemeery MN, Badr AN, Mohamed MA, Ghareeb DA. Validation of a serum microRNA panel as biomarkers for early diagnosis of hepatocellular carcinoma post-hepatitis C infection in Egyptian patients. *World J Gastroenterol* 2017; 23: 3864-3875 [PMID: 28638226 DOI: 10.3748/wjg.v23.i12.3864]
20. Sergeev AS, Agapova RK, Bogadil’nikova IV, Perel’man MI. [The use of discrete characters in discriminant analysis for diagnosis of pulmonary tuberculosis and for classification of patients differing in treatment efficiency based on polymorphisms at nine codominant loci-HP, GC, TF, PI, PGM1, GLO1, C3, ACP1 and ESD]. *Genetika* 2003; 39: 996-1002 [PMID: 12942785]
21. Cox JJ, Aliev AE, Curosy MM, Dawood M, Al-Mahtab M, Akbar SM, Rahman S, Riva A, Williams R, Taylor-Brandson SD. Urinary nuclear magnetic resonance spectroscopy of a Bangladeshi cohort with hepatitis-B hepatocellular carcinoma: A biomarker corroboration study. *World J Gastroenterol* 2016; 22: 4191-4200 [PMID: 27122669 DOI: 10.3748/wjg.v22.i16.4191]
22. Robin X, Turck N, Hainard A, Lisacek F, Sanchez JC, Müller M. Bioinformatics for proteins biomarker panel classification: what is needed to bring biomarker panels into in vitro diagnostics? *Expert Rev Proteomics* 2009; 6: 675-689 [PMID: 19929612 DOI: 10.1588/erp.09.83]
23. Min JH, Kim YK, Choi SY, Jeong WK, Lee JH, Wy SA, Ahn S, Ahn HS. Differentiation between cholangiocarcinoma and hepatocellular carcinoma with target sign on diffusion-weighted imaging and hepatobiliary phase gadoxetic acid-enhanced MR imaging: Classification tree analysis applying capsule and septum. *Eur J Radiol* 2017; 92: 1-10 [PMID: 28624005 DOI: 10.1016/j.ejrad.2017.04.008]
24. Vohradský J. Neural network model of gene expression. *FASEB J*
Xie H et al. Early detection of HCC

2001; 15: 846-854 [PMID: 11259403 DOI: 10.1096/fj.00-0361com]

Wu CF, Wu YJ, Liang PC, Wu CH, Peng SF, Chiu HW. Disease-free survival assessment by artificial neural networks for hepatocellular carcinoma patients after radiofrequency ablation. J Formos Med Assoc 2017; 116: 765-773 [PMID: 28117999 DOI: 10.1016/j.jfma.2016.12.006]

Chen QR, Vansant G, Oades K, Pickering M, Wei JS, Song YK, Monforte J, Khan J. Diagnosis of the small round blue cell tumors using multiplex polymerase chain reaction. J Mol Diagn 2007; 9: 80-88 [PMID: 17251339 DOI: 10.2353/jmoldx.2007.060111]

Nagel MA, Gilden D, Shade T, Gao B, Cohrs RJ. Rapid and sensitive detection of 68 unique varicella zoster virus gene transcripts in five multiplex reverse transcription-polymerase chain reactions. J Virol Methods 2009; 157: 62-68 [PMID: 19109999 DOI: 10.1016/j.jviromet.2008.11.019]

Gerke V, Creutz CE, Moss SE. Annexins: linking Ca2+ signalling to membrane dynamics. Nat Rev Mol Cell Biol 2005; 6: 449-461 [PMID: 15928709 DOI: 10.1038/nrm1661]

Ahn SH, Sawada H, Ro JY, Nicolson GL. Differential expression of annexin I in human mammary ductal epithelial cells in normal and benign and malignant breast tissues. Clin Exp Metastasis 1997; 15: 151-156 [PMID: 9062391]

Engström W, Ward A, Moorwood K. The role of scaffold proteins in JNK signaling. Cell Prolif 2010; 43: 56-66 [PMID: 19922489 DOI: 10.1111/j.1365-2184.2009.00654.x]

Kanoja D, Garg M, Gupta S, Gupta A, Suri A. Sperm-associated antigen 9, a novel biomarker for early detection of breast cancer. Cancer Epidemiol Biomarkers Prev 2009; 18: 630-639 [PMID: 19190149 DOI: 10.1158/1055-9965.EPI-08-0629]

Garg M, Kanoja D, Salhan S, Suri S, Gupta A, Lohiya NK, Suri A. Sperm-associated antigen 9 is a biomarker for early cervical carcinoma. Cancer 2009; 115: 2671-2683 [PMID: 19326449 DOI: 10.1002/cncr.24293]

Shen K, Xi Z, Xie J, Wang H, Xie C, Lee CS, Fahey P, Dong Q, Xu H. Guttiferone K suppresses cell motility and metastasis of hepatocellular carcinoma by restoring aberrantly reduced profilin 1. Oncotarget 2016; 7: 56650-56663 [PMID: 27494863 DOI: 10.18632/oncotarget.10992]

Zou L, Jaramillo M, Whaley D, Wells A, Panchapakesa V, Das T, Roy P. Profilin-1 is a negative regulator of mammary carcinoma aggressiveness. Br J Cancer 2007; 97: 1361-1371 [PMID: 17940506 DOI: 10.1038/sj.bjc.6604038]

Das T, Bae YH, Wells A, Roy P. Profilin-1 overexpression upregulates PTEN and suppresses AKT activation in breast cancer cells. J Cell Physiol 2009; 218: 436-443 [PMID: 18937284 DOI: 10.1002/jcp.21618]

P- Reviewer: Boeckxstaens GE, Lee MW  S- Editor: Chen K  L- Editor: Wang TQ  E- Editor: Huang Y
